L-163,491

Legal status

• US: Investigational drug

CAS Number

• 170969-73-0 ^Y

PubChem CID

• 9852384

ChemSpider

• ID8028096

L-163,491

Legal status
Legal status	US: Investigational drug
Identifiers
IUPAC name Butyl (4'-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5-(3-methoxybenzyl)-[1,1'-biphenyl]-2-yl)sulfonylcarbamate
CAS Number	170969-73-0 Y
PubChem CID	9852384
ChemSpider	ID8028096
UNII	ZF8TN281W9
ChEMBL	ChEMBL290214
Chemical and physical data
Formula	C36H40N4O5S
Molar mass	640.80 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCOC(=O)NS(=O)(=O)C1=C(C=C(C=C1)CC2=CC(=CC=C2)OC)C3=CC=C(C=C3)CN4C(=NC5=C4N=C(C=C5C)C)CC
InChI InChI=1S/C36H40N4O5S/c1-6-8-18-45-36(41)39-46(42,43)32-17-14-28(20-27-10-9-11-30(21-27)44-5)22-31(32)29-15-12-26(13-16-29)23-40-33(7-2)38-34-24(3)19-25(4)37-35(34)40/h9-17,19,21-22H,6-8,18,20,23H2,1-5H3,(H,39,41) Key:SRCIRAKBWHTYIX-UHFFFAOYSA-N

L-163,491 is an experimental drug which acts as a partial agonist of angiotensin II receptor type 1, and with lower affinity as an agonist of angiotensin II receptor type 2, mimicking the action of angiotensin II.^[1] Its practical applications to date have been limited to scientific research into the function of the angiotensin receptor system,^[2] but it has been suggested as a potential therapeutic agent for the treatment of inflammation of the lungs associated with certain viral diseases such as COVID-19.^[3][4]